ES2174931T3 - Anticuerpos monoclonales que se unen al precursor del antigeno de rechazo de tumores mage-1, mage-1 recombinante y peptidos inmunogenos derivados de mage-1. - Google Patents

Anticuerpos monoclonales que se unen al precursor del antigeno de rechazo de tumores mage-1, mage-1 recombinante y peptidos inmunogenos derivados de mage-1.

Info

Publication number
ES2174931T3
ES2174931T3 ES95907978T ES95907978T ES2174931T3 ES 2174931 T3 ES2174931 T3 ES 2174931T3 ES 95907978 T ES95907978 T ES 95907978T ES 95907978 T ES95907978 T ES 95907978T ES 2174931 T3 ES2174931 T3 ES 2174931T3
Authority
ES
Spain
Prior art keywords
mage
monoclonal antibodies
join
recombinant
precursor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95907978T
Other languages
English (en)
Inventor
Yao-Tseng Chen
Elisabeth Stockert
Yachi Chen
Pilar Garin-Chesa
Wolfgang J Rettig
Der Bruggen Pierre Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Memorial Sloan Kettering Cancer Center
Ludwig Cancer Research
Original Assignee
Ludwig Institute for Cancer Research Ltd
Memorial Sloan Kettering Cancer Center
Ludwig Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd, Memorial Sloan Kettering Cancer Center, Ludwig Cancer Research filed Critical Ludwig Institute for Cancer Research Ltd
Application granted granted Critical
Publication of ES2174931T3 publication Critical patent/ES2174931T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCION SE REFIERE A ANTICUERPOS MONOCLONALES QUE SE UNEN ESPECIFICAMENTE A LA MOLECULA PRECURSORA DEL ANTIGENO DE RECHAZO TUMORAL MAGE-1, HIBRIDOMAS QUE PRODUCEN ESTOS ANTICUERPOS MONOCLONALES, Y SU USO. TAMBIEN SE DESCRIBE UNA FORMA RECOMBINANTE DE MAGE-1, PEPTIDOS QUE TIENEN UTILIDAD COMO INMUNOGENOS, Y COMPUESTOS INMUNOGENICOS QUE CONTIENEN LOS PEPTIDOS Y UN ADYUVANTE.
ES95907978T 1994-02-01 1995-01-05 Anticuerpos monoclonales que se unen al precursor del antigeno de rechazo de tumores mage-1, mage-1 recombinante y peptidos inmunogenos derivados de mage-1. Expired - Lifetime ES2174931T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/190,411 US5541104A (en) 1991-05-23 1994-02-01 Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1

Publications (1)

Publication Number Publication Date
ES2174931T3 true ES2174931T3 (es) 2002-11-16

Family

ID=22701236

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95907978T Expired - Lifetime ES2174931T3 (es) 1994-02-01 1995-01-05 Anticuerpos monoclonales que se unen al precursor del antigeno de rechazo de tumores mage-1, mage-1 recombinante y peptidos inmunogenos derivados de mage-1.

Country Status (16)

Country Link
US (2) US5541104A (es)
EP (1) EP0752876B1 (es)
JP (1) JPH09511389A (es)
CN (1) CN1145032A (es)
AT (1) ATE215831T1 (es)
AU (1) AU686314B2 (es)
CA (1) CA2182369A1 (es)
DE (1) DE69526339T2 (es)
DK (1) DK0752876T3 (es)
ES (1) ES2174931T3 (es)
FI (1) FI963033A0 (es)
NO (1) NO963120L (es)
NZ (1) NZ279377A (es)
PT (1) PT752876E (es)
WO (1) WO1995020974A1 (es)
ZA (1) ZA95786B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE40089E1 (en) * 1991-05-23 2008-02-19 Ludwig Institute For Cancer Research Nucleic acid molecules encoding the MAGE-1 tumor rejection antigen precursor
US5925729A (en) * 1991-05-23 1999-07-20 Ludwig Institute For Cancer Research Tumor rejection antigen precursors, tumor rejection antigens and uses thereof
US6060257A (en) * 1994-06-03 2000-05-09 Ludwig Institute For Cancer Research Tumor rejection antigens presented by HLA-B44 molecules, and uses thereof
KR0185334B1 (ko) * 1995-11-02 1999-04-01 김은영 인간 혈장 아포지단백질 비-100에 결합하는 생쥐 항체를 암호하는 씨디엔에이
US5908778A (en) * 1996-10-03 1999-06-01 Ludwig Institute For Cancer Research Mage-10 encoding cDNA, the tumor rejection antigen precursor mage-10, antibodies specific to the molecule, and uses thereof
WO1999030734A1 (en) * 1997-12-18 1999-06-24 G.D. Searle & Co. Venezuelan equine encephalitis virus vectors expressing tumor-associated antigens to induce cancer immunity
ATE513042T1 (de) 1998-02-05 2011-07-15 Glaxosmithkline Biolog Sa Tumorassoziierte antigenderivate der mage-familie,nukleinsäuresequenzen, die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung
US7157091B1 (en) * 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules
ATE346925T1 (de) 2000-05-10 2006-12-15 Sanofi Pasteur Ltd Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
ATE527375T1 (de) 2001-04-12 2011-10-15 Imp Innovations Ltd Diagnose und behandlung von brustkrebs mit scn5a
ATE369895T1 (de) 2002-04-09 2007-09-15 Sanofi Pasteur Ltd Modifizierte cea nucleinsäure und expressionsvektoren
US8562970B2 (en) * 2003-10-08 2013-10-22 Sanofi Pasteur Limited Modified CEA/B7 vector
FR2889959A1 (fr) * 2005-09-01 2007-03-02 Commissariat Energie Atomique Epitopes t cd4+ des antigenes mage-a restreints a hla-dp4 et leurs applications
US8129184B2 (en) 2006-09-26 2012-03-06 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
US8871211B2 (en) 2006-09-28 2014-10-28 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
PL2328923T3 (pl) * 2008-09-02 2016-06-30 Cedars Sinai Medical Center Epitopy CD133
CA2774636C (en) 2009-09-25 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 and their use
GB201120860D0 (en) 2011-12-05 2012-01-18 Cambridge Entpr Ltd Cancer immunotherapy
US20140234351A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
WO2016094309A1 (en) 2014-12-10 2016-06-16 Myosotis Inhibition of tnf signaling in cancer immunotherapy
EP3744340A3 (en) 2015-07-16 2021-03-03 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
GB201519340D0 (en) 2015-11-02 2015-12-16 Cambridge Entpr Ltd Methods of T-lymphocyte expansion
GB201519481D0 (en) 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
GB201616238D0 (en) 2016-09-23 2016-11-09 Adaptimmune Ltd Modified T cells
RU2769513C2 (ru) 2017-01-05 2022-04-01 Кахр Медикал Лтд. Слитый белок pd1-4-1bbl и способы его применения
PL3565828T3 (pl) 2017-01-05 2022-04-04 Kahr Medical Ltd. Białko fuzyjne SIRP1 ALFA-41BBL i sposoby jego zastosowania
GB201700345D0 (en) 2017-01-09 2017-02-22 F-Star Beta Ltd Conditional agonists of immune responses
IL250916A0 (en) 2017-03-02 2017-06-29 Geiger Benjamin Methods for growing t cells in culture and their use
US20210187023A1 (en) 2017-06-27 2021-06-24 The Trustees Of Princeton University Compositions And Methods For Enhancing Immunotherapy
GB201713078D0 (en) 2017-08-15 2017-09-27 Adaptimmune Ltd T Cell Modification
CA3089154A1 (en) 2018-01-26 2019-08-01 Cambridge Enterprise Limited Peptide exchange protein
KR102945860B1 (ko) 2018-07-11 2026-03-31 카 메디컬 리미티드 SIRPalpha-4-1BBL 변이체 융합 단백질 및 이의 사용 방법
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
US12329816B2 (en) 2018-08-24 2025-06-17 The Trustees Of Princeton University Immunotherapy with metabolic enzyme expression
GB201820444D0 (en) 2018-12-14 2019-01-30 Adaptimmune Ltd Marker for T cell expansion
CN114375310A (zh) 2019-07-11 2022-04-19 卡尔医学有限公司 数个异二聚体及其数个使用方法
GB201911954D0 (en) 2019-08-20 2019-10-02 Adaptimmune Ltd Lentiviral transduction methods
US20230048361A1 (en) 2019-12-31 2023-02-16 Kahr Medical Ltd. Methods of culturing t cells and uses of same
US20230048719A1 (en) 2019-12-31 2023-02-16 Kahr Medical Ltd. Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same
IL276599A (en) 2020-08-09 2022-03-01 Yeda Res & Dev T cell receptor unique to mage-a1 and its uses
JP2024504912A (ja) 2020-12-30 2024-02-02 イミュノミック セラピューティックス， インコーポレイテッド 抗ｈｖｅｍ抗体
US20230310607A1 (en) 2021-11-09 2023-10-05 T-Knife Gmbh Methods of selecting a patient for treatment of a mage-a1 positive solid tumor, of predicting whether a patient being diagnosed with mage-a1 positive solid tumor will be responsive to treatment of this tumor and of treating a patient being diagnosed with such a mage-a1 positive solid tumor as well as corresponding pharmaceutical compositions and diagnostic kits
GB202303250D0 (en) 2023-03-06 2023-04-19 King S College London Method and compounds
WO2025155971A1 (en) 2024-01-19 2025-07-24 Immunomic Therapeutics, Inc Anti-activin receptor 1c (alk-7) receptor antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
KR950003005B1 (ko) * 1992-04-09 1995-03-29 주식회사 진흥전자 자동소변세척기
DE4224542A1 (de) * 1992-07-24 1994-01-27 Deutsches Krebsforsch Verfahren zur Herstellung von monoklonalen MHC Klasse I-puls-Peptid-restringierten Antikörpern

Also Published As

Publication number Publication date
AU686314B2 (en) 1998-02-05
AU1597995A (en) 1995-08-21
NO963120L (no) 1996-09-30
US5541104A (en) 1996-07-30
FI963033L (fi) 1996-07-31
WO1995020974A1 (en) 1995-08-10
CA2182369A1 (en) 1995-08-10
FI963033A7 (fi) 1996-07-31
EP0752876A4 (en) 1999-07-07
ZA95786B (en) 1995-10-09
EP0752876A1 (en) 1997-01-15
EP0752876B1 (en) 2002-04-10
DE69526339T2 (de) 2003-01-02
ATE215831T1 (de) 2002-04-15
DE69526339D1 (de) 2002-05-16
CN1145032A (zh) 1997-03-12
DK0752876T3 (da) 2002-05-21
US5843448A (en) 1998-12-01
NO963120D0 (no) 1996-07-26
FI963033A0 (fi) 1996-07-31
PT752876E (pt) 2002-09-30
JPH09511389A (ja) 1997-11-18
NZ279377A (en) 1997-07-27

Similar Documents

Publication Publication Date Title
PT752876E (pt) Anticorpos monoclonicos que se conectam com o percursor antigeneo de rejeicao de tumores mage-1, mage-1 recombinante, e peptidos imunogenicos derivados de mage-1
ES2146212T3 (es) Proteinas de union a antigenos trivalentes monoespecificas.
ATE144143T1 (de) Künstlicher impfstoff gegen aids-virus
DE69734109D1 (de) Humanisierung von anti-carcinoembryonalen Antigen anti-idiotypischen Antikörper und dessen Verwendung als Tumorvakzin und zur Markierung
AR037223A1 (es) Anticuerpos bloqueadores de cripto, composiciones que los comprenden, y metodos que los utilizan
SE9102974L (sv) Adenovira och vaerd till anvaendning foer framstaellning av hiv-proteiner och peptider
MX347883B (es) Anticuerpo monoclonal ds6, antigeno ca6 asociado con tumor, y metodos de uso de los mismos.
ES2167391T3 (es) Inmunoconjugados ii.
DK0710253T3 (da) Antistoffer, der er specifikke mod human prostatakirtel-kallikrein
ATE505542T1 (de) Tumorassoziierte antigenderivate der mage-familie,zur herstellung von fusionsproteinen mit t-helper epitope und zusammensetzungen zur impfung
TR200001946T2 (tr) Aşı
ES2158943T3 (es) Peptidos derivados del precursor del antigeno de rechazo tumoral mage-2 aislados, y usos de los mismos.
DE69333397D1 (de) Retro-, inverso-, und retro-inverso synthetische peptidanaloge
DK1089760T3 (da) Kunstige T-hjælpecelleepitoper som immunstimulatorer for syntetiske peptidimmunogener
ES2194836T3 (es) Peptidos para su uso en vacunacion e induccion de anticuerpos neutralizantes contra el virus de la inmunodeficiencia humana.
ES2126145T3 (es) Redireccionamiento de anticuerpos.
ES8601704A1 (es) Un polipeptido sintetico
ES2123558T3 (es) Antigenos peptidicos del vhc y procedimiento para la determinacion del vhc.
ES2177509T3 (es) Empleo de anticuerpos para la vacunacion contra el cancer.
ES2143996T3 (es) Antigenos peptidicos del hcv y procedimiento para la determinacion del hcv.
ATE188484T1 (de) Immunologisch mit hla homologe hiv protein epitope
ES2031834T3 (es) Benzazepinas fusionadas.
FI900230A0 (fi) Anti-idiotypa antikroppar mot antikroppar mot antigener med hoeg molekylvikt associerade till human melanoma.
ES2097207T3 (es) Receptor de poli-ig de sintesis, complejos receptor-anticuerpo, produccion y aplicacion de los mismos.
ES2087311T3 (es) Peptidos inductores de anticuerpos que inhiben los retrovirus del tipo hiv y anticuerpos dirigidos contra tales peptidos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 752876

Country of ref document: ES